Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

First molecular test is launched in Europe to identify SA and MRSA from nasal and wounds specimens

BD Diagnostics : 21 December, 2007  (New Product)
BD Diagnostics is launching the BD GeneOhm StaphSR assay for nasal and wound specimens as a CE marked product under the European In Vitro Diagnostics Directive.
The Assay is the first for the rapid and simultaneous identification and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) directly from nasal and wound specimens.

The Assay was CE marked for positive blood cultures earlier in the year. This Assay helps physicians rapidly administer the right antimicrobial treatment for patients with wounds infected with SA or MRSA. The Assay will also allow patients colonised with SA or MRSA to be decolonised and receive appropriate prophylactic antibiotics prior to surgery.

'Preoperative screening for nasal carriage of Staphylococus aureus and subsequent treatment of carriers with mupirocin nasal ointment is associated with significant reduction in the postoperative Staphylococcus aureus infection rate by more than 50 percent,' said Jan Kluytmans, MD, consultant microbiologist, Amphia Hospital Breda/Oosterhout, and professor of medical microbiology and infection control, VUmc, Amsterdam, The Netherlands.

'Healthcare workers around the world are diligently attempting to control transmission and infection caused by multidrug-resistant organisms, such as MRSA,' said Vince Forlenza, executive vice president, BD. 'CE marking for all three specimen claims for the BD GeneOhm StaphSR Assay reflects BD's commitment to providing high-quality diagnostic tests in the battle against staphylococcal infections.'

A recent study reported in the Journal of American Medical Association estimates that 94,360 patients acquire an invasive MRSA infection each year, leading to an estimated 18,650 deaths in the USA. MRSA has become the most common cause of skin and soft tissue infections (SSTIs), often presenting as a ‘spider bite’, but has also been associated with sepsis and necrotising pneumonia.

Recent studies have shown a dramatic increase in patients suffering from SSTIs, with SA found to be the causative pathogen in 76 percent of cases. Of these SA isolates, 78 percent were MRSA. Although the vast majority of patients with MRSA SSTIs in the studies received empirical antimicrobial therapy, more than half of the time the prescribed agent was not active against MRSA.

The BD GeneOhm StaphSR Assay is currently pending FDA clearance for various specimen types. BD is also developing rapid molecular tests for the detection of two other organisms that cause severe healthcare-associated infections. These tests will identify the vanA and vanB genes associated with vancomycin-resistant enterococci and the toxin gene associated with Clostridium difficile.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo